Search

Displaying results 8021 - 8030 of 8133 in total
  1. Drug

    Zosuquidar

    go.drugbank.com/drugs/DB06191
    Investigational

    Its action mechanism consists of the inhibition of P-glycoproteins; other drugs with this mechanism include tariquidar and laniquidar.

    Categories: P-glycoprotein inhibitors
  2. Drug

    Vadimezan

    go.drugbank.com/drugs/DB06235
    Investigational

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates
  3. Drug

    Sitaxentan

    go.drugbank.com/drugs/DB06268
    ApprovedWithdrawn

    Sitaxentan was marketed under the trade name Thelin for the treatment of pulmonary arterial hypertension (PAH) by Encysive Pharmaceuticals until Pfizer purchased Encysive in February 2008. In 2010, Pfizer voluntarily removed sitaxentan f...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C19 Inhibitors
  4. Drug

    Indisulam

    go.drugbank.com/drugs/DB06370
    Investigational

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Substrates
  5. Drug

    Annamycin

    go.drugbank.com/drugs/DB06420
    Investigational

    Categories: P-glycoprotein inhibitors
  6. Drug

    Deramciclane

    go.drugbank.com/drugs/DB06512
    Investigational

    Deramciclane (EGIS-3886) is used for the treatment of a number of anxiety disorders. Deramciclane differs from other anti anxiety medications in that it is not a benzodiazepine and so has a different structure and target. It antagonizes ...

    Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 Enzyme Inhibitors
  7. Drug

    Esmirtazapine

    go.drugbank.com/drugs/DB06678
    Investigational

    Esmirtazapine, known by the standardized identifier SCH 900265, was under development by Organon to treat insomnia and vasomotor symptoms associated with menopause. Esmirtazapine is the (S)-(+)-enantiomer of mirtazapine and possesses sim...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Substrates
  8. Drug

    Lornoxicam

    go.drugbank.com/drugs/DB06725
    ApprovedInvestigational

    Lornoxicam (chlortenoxicam) is a new nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic, anti-inflammatory and antipyretic properties. Lornoxicam differs from other oxicam compounds in its potent inhibition of...

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 Substrates
  9. Drug

    Bufuralol

    go.drugbank.com/drugs/DB06726
    Experimental

    Bufuralol is a new, non-selective -adrenoceptor blocking agent.

    Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Substrates
  10. Drug

    Besifloxacin

    go.drugbank.com/drugs/DB06771
    Approved

    Besifloxacin is a fourth generation fluoroquinolone-type opthalmic antibiotic for the treatment of bacterial conjunctivitis. FDA approved on May 28, 2009.

    Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme Inhibitors